Ocana, Jesus A.Bell, Maria C.Heskett, Jordan B.Baker, William H.Mousdicas, NicoTurner, Matthew J.2019-08-262019-08-262019-05-25Ocana, J. A., Bell, M. C., Heskett, J. B., Baker, W. H., Mousdicas, N., & Turner, M. J. (2019). Treatment of estrogen-induced dermatitis with omalizumab. JAAD case reports, 5(6), 481–483. doi:10.1016/j.jdcr.2019.03.007https://hdl.handle.net/1805/20575In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1 Fifty years later, Shelley et al,2 who introduced the concept of progesterone dermatitis several decades prior, defined estrogen dermatitis based on studies of 7 women with premenstrual flares of skin eruptions including papulovesicular, urticarial, or eczematous lesions or generalized pruritus. Previously described therapies for estrogen dermatitis include estrogen desensitization, tamoxifen, leuprolide, and oophorectomy.3 Here we report a case of estrogen-induced dermatitis successfully treated with omalizumab.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesEstrogen-induced dermatitisMast cellsOmalizumabArticle